IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine

Pub Date : 2026-03-07 Epub Date: 2026-01-18 DOI: 10.1016/j.vaccine.2026.128239

So Yoon Sim , Sheetal Silal , Raymond CW Hutubessy , Naor Bar-Zeev , Katherine L O'Brien , Philipp Lambach

引用次数: 0

Corrigendum to “Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms” [Vaccine 68 (2025) 127942] “通过白细胞中基因的体外激活纵向监测细胞免疫（EAGL）试验突出了mRNA - COVID-19疫苗对突破性症状有效性的潜在标记物”[疫苗68(2025)127942]的勘误表

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine

Pub Date : 2026-03-07 Epub Date: 2026-01-29 DOI: 10.1016/j.vaccine.2026.128267

Taro Saito , Arnaud Couzinet , Toshihiro Suzuki , Manami Shimomura , Akihide Ryo , Kei Miyakawa , Yuki Katayama , Tetsuya Nakatsura

引用次数: 0

Pharmacy access and shingles vaccinations in the US: a propensity score matching analysis 药房准入和带状疱疹疫苗接种在美国：倾向得分匹配分析

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine

Pub Date : 2026-03-07 Epub Date: 2026-01-30 DOI: 10.1016/j.vaccine.2026.128256

Rachel Wittenauer , Parth D. Shah , Jennifer L. Bacci , Stephen J. Mooney , Andy Stergachis

Importance

Community pharmacists provide many important healthcare services, including routine adult vaccinations. However, an estimated 15.8 million people in the US live in pharmacy deserts and may lack access to these services. The relationship between pharmacy deserts and adult vaccine receipt has yet to be thoroughly explored empirically.

Objective

We evaluated the relationship between census tract-level pharmacy access and shingles vaccination receipt.

Design, setting, and participants

This propensity score matched analysis used 2022 vaccination data from seven collaborating State Departments of Health: Colorado, Louisiana, Massachusetts, Nevada, Oklahoma, Washington, and Wisconsin. Census tracts in those states were classified based on their access to community pharmacies in April 2022. The dataset for analysis contained 9652 census tracts representing 13.7 million adults aged 50+ years.

Exposure

Our primary exposure was whether a census tract was a “pharmacy desert”, defined as being both low-income and having low geographic access to pharmacies. Our secondary exposure was whether a tract had low geographic access to pharmacies regardless of income status of that tract.

Main outcomes

The primary outcome was completed shingles vaccinations per 1000 population age 50+ years in 2022.

Results

Pharmacy deserts had 0.4 fewer shingles vaccinations per 1000 population (p = 0.83; 95% CI -3.8, 3.6) compared to matched non-pharmacy-desert tracts. Our secondary analysis indicated that low-access tracts had 2.4 fewer vaccinations per 1000 population (p = 0.004, 95% CI: −3.9, −0.7).

Conclusions

Low pharmacy access is associated with lower rates of shingles vaccination. The definition of pharmacy desert that includes a low-income criterion may not add further precision in identifying areas with inadequate access to pharmacy-based vaccinations. Efforts at the state and national levels to prevent pharmacy closures and support pharmacists in delivering care may improve access to important pharmacy services such as vaccination.

社区药剂师提供许多重要的卫生保健服务，包括成人常规疫苗接种。然而，据估计，美国有1580万人生活在药房沙漠中，可能无法获得这些服务。药房荒漠与成人疫苗收货之间的关系还有待深入的实证研究。目的探讨人口普查基层药房可及性与带状疱疹疫苗接种率的关系。设计、设置和参与者该倾向评分匹配分析使用了来自七个合作州卫生部的2022年疫苗接种数据：科罗拉多州、路易斯安那州、马萨诸塞州、内华达州、俄克拉荷马州、华盛顿州和威斯康星州。这些州的人口普查区是根据他们在2022年4月获得社区药店的情况进行分类的。用于分析的数据集包含9652个人口普查区，代表1370万50岁以上的成年人。暴露我们的主要暴露是一个人口普查区是否是“药房沙漠”，定义为低收入和地理上难以获得药店。我们的二次暴露是，无论该地区的收入状况如何，该地区是否具有较低的药房地理可及性。主要结局：主要结局是2022年每1000名50岁以上人口完成带状疱疹疫苗接种。结果药房沙漠地区每1000人的带状疱疹疫苗接种率比非药房沙漠地区低0.4人（p = 0.83; 95% CI -3.8, 3.6）。我们的二次分析表明，低通道地区每1000人的疫苗接种率减少2.4次（p = 0.004, 95% CI: - 3.9, - 0.7）。结论药房可及性慢与带状疱疹疫苗接种率低有关。包括低收入标准的药房沙漠的定义可能无法进一步精确地确定无法充分获得基于药房的疫苗接种的地区。在州和国家一级防止药房关闭和支持药剂师提供护理的努力，可能会改善获得疫苗接种等重要药房服务的机会。

{"title":"Pharmacy access and shingles vaccinations in the US: a propensity score matching analysis","authors":"Rachel Wittenauer , Parth D. Shah , Jennifer L. Bacci , Stephen J. Mooney , Andy Stergachis","doi":"10.1016/j.vaccine.2026.128256","DOIUrl":"10.1016/j.vaccine.2026.128256","url":null,"abstract":"<div><h3>Importance</h3><div>Community pharmacists provide many important healthcare services, including routine adult vaccinations. However, an estimated 15.8 million people in the US live in pharmacy deserts and may lack access to these services. The relationship between pharmacy deserts and adult vaccine receipt has yet to be thoroughly explored empirically.</div></div><div><h3>Objective</h3><div>We evaluated the relationship between census tract-level pharmacy access and shingles vaccination receipt.</div></div><div><h3>Design, setting, and participants</h3><div>This propensity score matched analysis used 2022 vaccination data from seven collaborating State Departments of Health: Colorado, Louisiana, Massachusetts, Nevada, Oklahoma, Washington, and Wisconsin. Census tracts in those states were classified based on their access to community pharmacies in April 2022. The dataset for analysis contained 9652 census tracts representing 13.7 million adults aged 50+ years.</div></div><div><h3>Exposure</h3><div>Our primary exposure was whether a census tract was a “pharmacy desert”, defined as being both low-income and having low geographic access to pharmacies. Our secondary exposure was whether a tract had low geographic access to pharmacies regardless of income status of that tract.</div></div><div><h3>Main outcomes</h3><div>The primary outcome was completed shingles vaccinations per 1000 population age 50+ years in 2022.</div></div><div><h3>Results</h3><div>Pharmacy deserts had 0.4 fewer shingles vaccinations per 1000 population (<em>p</em> = 0.83; 95% CI -3.8, 3.6) compared to matched non-pharmacy-desert tracts. Our secondary analysis indicated that low-access tracts had 2.4 fewer vaccinations per 1000 population (<em>p</em> = 0.004, 95% CI: −3.9, −0.7).</div></div><div><h3>Conclusions</h3><div>Low pharmacy access is associated with lower rates of shingles vaccination. The definition of pharmacy desert that includes a low-income criterion may not add further precision in identifying areas with inadequate access to pharmacy-based vaccinations. Efforts at the state and national levels to prevent pharmacy closures and support pharmacists in delivering care may improve access to important pharmacy services such as vaccination.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128256"},"PeriodicalIF":4.5,"publicationDate":"2026-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond the shot: A framework of individual and external influences on U.S. young adults' COVID-19 vaccination decisions derived from thematic analysis 注射之外：基于主题分析的美国年轻人COVID-19疫苗接种决策的个人和外部影响框架

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine

Pub Date : 2026-03-07 Epub Date: 2026-01-28 DOI: 10.1016/j.vaccine.2026.128283

Hyeouk Chris Hahm , Michael Tang , Logan Lupaczyk , Jinwon Lee , Yahni Lapa , Joyce Lam , Uyen-Sa D.T. Nguyen , Yvette C. Cozier

Understanding vaccine decision-making among young adults is critical for shaping effective public health responses during and beyond the COVID-19 pandemic. This qualitative study investigates two key questions: (1) What are the reasons young adults choose to be vaccinated or remain unvaccinated against COVID-19? (2) What distinct attitudinal groups emerge based on these reasons? This cross-sectional online study assessed 1863 unique open-ended free-text responses provided by 1863 U.S. young adults between February 14 and June 15, 2022. The data originated from the COVID-19 Adult Resilience Experiences Study (CARES). Participants reported their vaccination status and then shared free-text explanations of their decision. Thematic analysis led to the development of the “COVID-19 Vaccination Attitudes Among Young Adults” model, illustrating how vaccination decisions were shaped by the dynamic interplay of individual and contextual factors. At the individual level, pro-vaccination, vaccine-hesitant, and anti-vaccination attitudes emerged. Pro-vaccination individuals emphasized motivations such as protecting health, trusting in science and institutions, and having a sense of collective responsibility. Vaccine-hesitant respondents were marked by uncertainty, including a fear of unknown risks and decision paralysis. Anti-vaccination individuals expressed distrust in governmental and scientific authorities, had a strong emphasis on personal autonomy, and expressed beliefs rooted in spiritual, naturalistic, or fatalistic frameworks. Beyond the individual level, three contextual influences shaped attitudes: government policies and mandates, social influence from other people around them, and vaccine accessibility. A key distinction across these groups was between collectivistic and individualistic motivations. Vaccine-hesitant individuals were characterized by ambivalence. COVID-19 vaccination attitudes among U.S. young adults reflect a complex intersection of personal beliefs and social context. Understanding these patterns can inform more nuanced public health strategies and communication efforts.

了解年轻人的疫苗决策对于在COVID-19大流行期间和之后形成有效的公共卫生应对措施至关重要。本定性研究调查了两个关键问题：(1)年轻人选择接种或不接种COVID-19疫苗的原因是什么？(2)基于这些原因，出现了哪些不同的态度群体？这项横断面在线研究评估了1863年美国年轻人在2022年2月14日至6月15日期间提供的1863个独特的开放式自由文本回复。数据来自2019冠状病毒病成人复原力体验研究（CARES）。参与者报告了他们的疫苗接种状况，然后分享了他们决定的自由文本解释。专题分析促成了“青年人对COVID-19疫苗接种态度”模型的发展，说明了疫苗接种决策是如何受到个人因素和环境因素动态相互作用的影响。在个人层面上，出现了支持接种疫苗、对接种疫苗犹豫不决和反对接种疫苗的态度。支持接种疫苗的个人强调了保护健康、信任科学和机构以及具有集体责任感等动机。对疫苗犹豫不决的应答者表现出不确定性，包括对未知风险的恐惧和决策瘫痪。反对接种疫苗的个人表达了对政府和科学权威的不信任，强烈强调个人自主权，并表达了植根于精神、自然主义或宿命论框架的信仰。在个人层面之外，三种环境影响影响了态度：政府政策和命令，周围其他人的社会影响，以及疫苗的可及性。这些群体的一个关键区别是集体主义动机和个人主义动机。疫苗犹豫个体的特点是矛盾心理。美国年轻人对COVID-19疫苗接种的态度反映了个人信仰和社会背景的复杂交集。了解这些模式可以为更细致的公共卫生战略和沟通工作提供信息。

{"title":"Beyond the shot: A framework of individual and external influences on U.S. young adults' COVID-19 vaccination decisions derived from thematic analysis","authors":"Hyeouk Chris Hahm , Michael Tang , Logan Lupaczyk , Jinwon Lee , Yahni Lapa , Joyce Lam , Uyen-Sa D.T. Nguyen , Yvette C. Cozier","doi":"10.1016/j.vaccine.2026.128283","DOIUrl":"10.1016/j.vaccine.2026.128283","url":null,"abstract":"<div><div>Understanding vaccine decision-making among young adults is critical for shaping effective public health responses during and beyond the COVID-19 pandemic. This qualitative study investigates two key questions: (1) What are the reasons young adults choose to be vaccinated or remain unvaccinated against COVID-19? (2) What distinct attitudinal groups emerge based on these reasons? This cross-sectional online study assessed 1863 unique open-ended free-text responses provided by 1863 U.S. young adults between February 14 and June 15, 2022. The data originated from the COVID-19 Adult Resilience Experiences Study (CARES). Participants reported their vaccination status and then shared free-text explanations of their decision. Thematic analysis led to the development of the “COVID-19 Vaccination Attitudes Among Young Adults” model, illustrating how vaccination decisions were shaped by the dynamic interplay of individual and contextual factors. At the individual level, pro-vaccination, vaccine-hesitant, and anti-vaccination attitudes emerged. Pro-vaccination individuals emphasized motivations such as protecting health, trusting in science and institutions, and having a sense of collective responsibility. Vaccine-hesitant respondents were marked by uncertainty, including a fear of unknown risks and decision paralysis. Anti-vaccination individuals expressed distrust in governmental and scientific authorities, had a strong emphasis on personal autonomy, and expressed beliefs rooted in spiritual, naturalistic, or fatalistic frameworks. Beyond the individual level, three contextual influences shaped attitudes: government policies and mandates, social influence from other people around them, and vaccine accessibility. A key distinction across these groups was between collectivistic and individualistic motivations. Vaccine-hesitant individuals were characterized by ambivalence. COVID-19 vaccination attitudes among U.S. young adults reflect a complex intersection of personal beliefs and social context. Understanding these patterns can inform more nuanced public health strategies and communication efforts.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128283"},"PeriodicalIF":4.5,"publicationDate":"2026-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neonatal mice immune response to COVID-19 mRNA vaccine 新生小鼠对COVID-19 mRNA疫苗的免疫应答

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine

Pub Date : 2026-03-07 Epub Date: 2026-01-28 DOI: 10.1016/j.vaccine.2026.128271

Leda Lotspeich-Cole , Mukesh Kumar Jha , Swetha Parvathaneni , Robert C. Lee , Drew Weissman , Marian Major , Mustafa Akkoyunlu

A vaccine based on an mRNA platform was first licensed for human use during the COVID-19 pandemic. However, data on the immunogenicity of SARS-CoV-2 mRNA vaccines in neonates is insufficient and the vaccines were only authorized for those over six months of age. Here, we compared the antibody responses induced by both recombinant receptor binding domain (rRBD) of SARS-CoV-2 spike protein (RBD) and mRNA encoded RBD (RBD-mRNA-LNP) forms in neonatal mice. When administered twice three weeks apart, both forms induced detectable anti-RBD antibodies. However, levels of IgG antibodies against RBD were significantly higher with more potent inhibition of RBD binding to ACE2 in neonatal mice immunized with RBD-mRNA-LNP vaccine compared to those immunized with rRBD vaccine adjuvanted with AddaVax™, a squalene-based adjuvant. Thus, the mRNA vaccine platform elicits higher levels of antibodies with improved functional capability in neonatal mice compared to the recombinant protein platform.

基于mRNA平台的疫苗在2019冠状病毒病大流行期间首次获准用于人类。然而，关于SARS-CoV-2 mRNA疫苗在新生儿中的免疫原性的数据不足，疫苗仅被批准用于6个月以上的婴儿。在此，我们比较了SARS-CoV-2刺突蛋白（RBD）重组受体结合域（rRBD）和mRNA编码RBD （RBD-mRNA- lnp）两种形式在新生小鼠中诱导的抗体反应。当间隔三周给药两次时，两种形式均诱导可检测到的抗rbd抗体。然而，与以角鲨烯为基础的佐剂AddaVax™佐剂的rRBD疫苗免疫的新生小鼠相比，接种RBD- mrna - lnp疫苗免疫的新生小鼠抗RBD的IgG抗体水平明显更高，并且更有效地抑制RBD与ACE2的结合。因此，与重组蛋白平台相比，mRNA疫苗平台在新生小鼠中引发了更高水平的抗体，并改善了其功能能力。

引用次数: 0

Protective properties of a candidate C-terminal domain OspA vaccine for prevention of Lyme disease 一种候选c端结构域OspA疫苗预防莱姆病的保护特性

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine

Pub Date : 2026-03-07 Epub Date: 2026-01-29 DOI: 10.1016/j.vaccine.2026.128231

Monica E. Embers , Nicole R. Hasenkampf , Amanda C. Tardo , Yekaterina Timofeyeva , Sabine Wellnitz , Yan Li , Alexey Gribenko , Jeong-Jin Park , Alexandre Esadze , Sirena Tran , Jun Sun , Jill Dane , Donna Giordano-Schmidt , Guy Singh , Michelle Gaylord , Danielle Baranova , Andreas Meinke , Urban Lundberg , Romana Hochreiter , Sandra Jost , Raphael Simon

Lyme disease is a growing public health concern that is geographically focused in regions where ticks that carry the causative bacteria, Borrelia burgdorferi sensu lato (s.l.), are endemic. Outer surface protein A (OspA) is expressed by B. burgdorferi s.l. spirochetes during the tick phase and OspA antibodies introduced during tick feeding can block transmission and prevent B. burgdorferi infection. Candidate Lyme disease vaccine VLA15 is comprised of the C-terminal domains of the six B. burgdorferi s.l. OspA serotypes (ST) prevalent in North America and Europe. We report herein that non-human primates immunized with VLA15 were protected against challenge with Ixodes scapularis ticks bearing B. burgdorferi sensu stricto (s.s.) (OspA ST1). Levels of residual B. burgdorferi s.s. tick colonization were reduced in ticks that fed on VLA15-immunized primates compared to those immunized with full length-OspA ST1 (FL-OspA) at a point when OspA-binding IgG levels were similar. Furthermore, monoclonal antibodies targeting the C-terminal half of OspA, elicited by FL-OspA immunization in primates, were more effective at complement-mediated bactericidal killing in vitro and clearance of spirochetes in ticks versus those directed against other parts of the protein.

莱姆病是一个日益严重的公共卫生问题，在地理上主要集中在携带致病细菌伯氏疏螺旋体（s.l）的蜱虫流行的地区。外表面蛋白A （OspA）在蜱虫期由伯氏疏螺旋体表达，在蜱虫摄食过程中引入OspA抗体可阻断传播，预防伯氏疏螺旋体感染。候选莱姆病疫苗VLA15由流行于北美和欧洲的6种伯氏疏螺旋体（B. burgdorferi s.l. OspA）血清型（ST）的c端结构域组成。我们在此报告了用VLA15免疫的非人灵长类动物免受携带严格的伯氏疏螺旋体的肩胛骨伊蚊蜱的攻击。(OspA相约)。在ospa结合IgG水平相似的情况下，以vlad15免疫的灵长类动物为食的蜱与全长- ospa ST1 （FL-OspA）免疫的蜱的残余伯氏疏螺旋体定植水平降低。此外，在灵长类动物中，通过FL-OspA免疫引发的针对OspA c端一半的单克隆抗体，在补体介导的体外杀菌和蜱虫螺旋体清除方面比针对该蛋白其他部分的单克隆抗体更有效。

{"title":"Protective properties of a candidate C-terminal domain OspA vaccine for prevention of Lyme disease","authors":"Monica E. Embers , Nicole R. Hasenkampf , Amanda C. Tardo , Yekaterina Timofeyeva , Sabine Wellnitz , Yan Li , Alexey Gribenko , Jeong-Jin Park , Alexandre Esadze , Sirena Tran , Jun Sun , Jill Dane , Donna Giordano-Schmidt , Guy Singh , Michelle Gaylord , Danielle Baranova , Andreas Meinke , Urban Lundberg , Romana Hochreiter , Sandra Jost , Raphael Simon","doi":"10.1016/j.vaccine.2026.128231","DOIUrl":"10.1016/j.vaccine.2026.128231","url":null,"abstract":"<div><div>Lyme disease is a growing public health concern that is geographically focused in regions where ticks that carry the causative bacteria, <em>Borrelia burgdorferi</em> sensu lato (s.l.), are endemic. Outer surface protein A (OspA) is expressed by <em>B. burgdorferi</em> s.l. spirochetes during the tick phase and OspA antibodies introduced during tick feeding can block transmission and prevent <em>B. burgdorferi</em> infection. Candidate Lyme disease vaccine VLA15 is comprised of the C-terminal domains of the six <em>B. burgdorferi</em> s.l. OspA serotypes (ST) prevalent in North America and Europe. We report herein that non-human primates immunized with VLA15 were protected against challenge with <em>Ixodes scapularis</em> ticks bearing <em>B. burgdorferi</em> sensu stricto (s.s.) (OspA ST1). Levels of residual <em>B. burgdorferi</em> s.s. tick colonization were reduced in ticks that fed on VLA15-immunized primates compared to those immunized with full length-OspA ST1 (FL-OspA) at a point when OspA-binding IgG levels were similar. Furthermore, monoclonal antibodies targeting the C-terminal half of OspA, elicited by FL-OspA immunization in primates, were more effective at complement-mediated bactericidal killing <em>in vitro</em> and clearance of spirochetes in ticks versus those directed against other parts of the protein.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128231"},"PeriodicalIF":4.5,"publicationDate":"2026-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Direct comparison of three herpes simplex virus-2 vaccine candidates using peripheral or mucosal routes of vaccination 三种单纯疱疹病毒-2候选疫苗外周或粘膜接种途径的直接比较

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine

Pub Date : 2026-03-07 Epub Date: 2026-02-01 DOI: 10.1016/j.vaccine.2025.128107

Kening Wang , Tristan Jordan , Lui Suzuki-Williams , Jing Qin , David M. Knipe , Jeffrey I. Cohen

Despite decades of research, no vaccine has been approved for herpes simplex virus-2 (HSV-2). While HSV-2 subunit vaccines have been more extensively studied, various HSV-2 mutants have also been tested. We compared three types of HSV-2 mutant viruses (replication-defective, single-cycle replication, and replication-competent) using five routes of vaccination (intramuscular, subcutaneous at two different sites, intrarectal, or intravaginal) for their ability to protect mice from intravaginal challenge with HSV-2. The replication-competent virus vaccine gave the best protection compared to the other vaccines after intravaginal vaccination of mice resulting in complete prevention of disease, and 90 % of the animals had no detectable shedding after challenge despite very low serum neutralizing titers. The replication-competent virus vaccine was also superior to the other vaccines when given intrarectally, although less effective than when given intravaginally. In contrast, when given subcutaneously in the scruff of the neck, the replication-defective vaccine was more effective than the replication-competent vaccine and the replication-defective vaccine tended to be more effective than the live vaccine when given intramuscularly. The highest levels of serum neutralizing antibody were observed with the replication-defective and single-cycle replication vaccines given intramuscularly. Thus, excellent protection from genital herpes was obtained after intravaginal vaccination with the replication-competent vaccine providing evidence that a replication-competent vaccine given by the natural route of HSV-2 infection is superior to replication-defective or single-cycle replication vaccines to reduce virus infection and spread in the genital mucosa.

尽管经过几十年的研究，还没有一种疫苗被批准用于单纯疱疹病毒2型（HSV-2）。虽然对2型单纯疱疹病毒亚单位疫苗进行了更广泛的研究，但也对各种2型单纯疱疹病毒突变体进行了测试。我们比较了三种类型的HSV-2突变病毒（复制缺陷型、单周期复制型和复制能力型）通过五种接种途径（肌肉注射、两个不同部位皮下注射、直肠内注射或阴道内注射）保护小鼠免受HSV-2阴道内攻击的能力。与其他疫苗相比，在阴道内接种小鼠后，复制能力强的病毒疫苗提供了最好的保护，从而完全预防疾病，90%的动物在攻击后没有可检测到的脱落，尽管血清中和滴度非常低。当直肠内注射时，复制能力病毒疫苗也优于其他疫苗，尽管效果不如阴道内注射。相反，当颈部皮下注射复制缺陷疫苗时，复制缺陷疫苗比复制活性疫苗更有效，当肌肉注射时，复制缺陷疫苗往往比活疫苗更有效。肌肉注射复制缺陷疫苗和单循环复制疫苗时，血清中和抗体水平最高。因此，阴道内接种复制活性疫苗对生殖器疱疹具有良好的保护作用，这证明通过HSV-2感染的自然途径接种的复制活性疫苗在减少病毒在生殖器粘膜中的感染和传播方面优于复制缺陷疫苗或单周期复制疫苗。

{"title":"Direct comparison of three herpes simplex virus-2 vaccine candidates using peripheral or mucosal routes of vaccination","authors":"Kening Wang , Tristan Jordan , Lui Suzuki-Williams , Jing Qin , David M. Knipe , Jeffrey I. Cohen","doi":"10.1016/j.vaccine.2025.128107","DOIUrl":"10.1016/j.vaccine.2025.128107","url":null,"abstract":"<div><div>Despite decades of research, no vaccine has been approved for herpes simplex virus-2 (HSV-2). While HSV-2 subunit vaccines have been more extensively studied, various HSV-2 mutants have also been tested. We compared three types of HSV-2 mutant viruses (replication-defective, single-cycle replication, and replication-competent) using five routes of vaccination (intramuscular, subcutaneous at two different sites, intrarectal, or intravaginal) for their ability to protect mice from intravaginal challenge with HSV-2. The replication-competent virus vaccine gave the best protection compared to the other vaccines after intravaginal vaccination of mice resulting in complete prevention of disease, and 90 % of the animals had no detectable shedding after challenge despite very low serum neutralizing titers. The replication-competent virus vaccine was also superior to the other vaccines when given intrarectally, although less effective than when given intravaginally. In contrast, when given subcutaneously in the scruff of the neck, the replication-defective vaccine was more effective than the replication-competent vaccine and the replication-defective vaccine tended to be more effective than the live vaccine when given intramuscularly. The highest levels of serum neutralizing antibody were observed with the replication-defective and single-cycle replication vaccines given intramuscularly. Thus, excellent protection from genital herpes was obtained after intravaginal vaccination with the replication-competent vaccine providing evidence that a replication-competent vaccine given by the natural route of HSV-2 infection is superior to replication-defective or single-cycle replication vaccines to reduce virus infection and spread in the genital mucosa.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128107"},"PeriodicalIF":4.5,"publicationDate":"2026-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of rabies immunoglobulins and monoclonal antibodies infiltrated into animal bite wounds after dilution: Real-world evidence from an anti-rabies clinic in India 狂犬病免疫球蛋白和单克隆抗体稀释后渗入动物咬伤伤口的有效性：来自印度一家抗狂犬病诊所的真实证据

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine

Pub Date : 2026-03-07 Epub Date: 2026-01-22 DOI: 10.1016/j.vaccine.2026.128233

D.H. Ashwath Narayana , M.K. Poornima , C.M. Chiranthan , H.S. Ravish , Reeta S. Mani , Shrikrishna Isloor , R. Sharada , M.K. Sudarshan

Background

WHO recommends infiltration of category III bite wounds, and category II wounds in immunocompromised individuals, with rabies immunoglobulins (RIG) to neutralize the virus at the site of exposure. Dilution with sterile normal saline is advised to ensure adequate wound infiltration. However, data on the extent of dilution across various RIGs and rabies monoclonal antibodies (RmAbs), and their effectiveness are lacking. This study aimed to generate evidence on dilution practices and outcomes following full-dose infiltration.

Objectives

To review the dilution ratios of RIGs and RmAbs used for full-dose wound infiltration in routine practice, and assess the clinical outcomes of the exposed individuals.

Methods

A desk review was conducted on 223 animal bite cases managed at an Anti-Rabies Clinic, Bengaluru, India from January 2022 to December 2024. All animal bite victims received full-dose RIG or RmAb, diluted with normal saline as required for complete wound infiltration. Survival status was verified through telephonic follow-up.

Results

Of the 223 cases, 133 (60%) were males, 210 (94%) cases had dog bites, 71 (31.8%) had bite from suspect rabid animals.Among 210 cases who had dog bites, 65 (31%) were attributed to suspect rabid dogs. Dilution ratios reached up to 1:1 for HRIG, 1:5.4 for ERIG, 1:20.7 for Rabishield, and 1:8.2 for Twinrab. Special groups included one pregnant woman (Twinrab) and one woman on antiretroviral therapy (Rabishield). Survival was 100%, with no rabies cases observed during 6–42 months of follow-up.

Conclusion

Diluted RIGs and RmAbs were found to be effective in preventing rabies when used for adequate infiltration of multiple and severe animal bite wounds, supporting the feasibility and safety of dilution practices in real-world clinical settings.

世卫组织建议使用狂犬病免疫球蛋白（RIG）浸润III类咬伤伤口和免疫功能低下个体的II类伤口，以在接触部位中和病毒。建议用无菌生理盐水稀释，以确保足够的伤口浸润。然而，关于各种rig和狂犬病单克隆抗体（rmab）的稀释程度及其有效性的数据缺乏。本研究旨在为全剂量浸润后的稀释操作和结果提供证据。目的探讨常规全剂量创面浸润中rig与rmab的稀释比，评价暴露个体的临床结果。方法对2022年1月至2024年12月在印度班加罗尔某狂犬病诊所治疗的223例动物咬伤病例进行回顾性分析。所有动物咬伤患者均接受全剂量RIG或RmAb治疗，并根据伤口完全浸润的需要用生理盐水稀释。通过电话随访确认生存状况。结果223例病例中，男性133例（60%），犬咬伤210例（94%），疑似狂犬病动物咬伤71例（31.8%）。在210例被狗咬伤的病例中，65例（31%）归因于疑似患狂犬病的狗。HRIG的稀释比例高达1:1，ERIG为1:5.4，Rabishield为1:20.7，Twinrab为1:8.2。特殊群体包括一名孕妇（Twinrab）和一名接受抗逆转录病毒治疗的妇女（Rabishield）。生存率为100%，随访6-42个月未见狂犬病病例。结论经稀释的rig和rmab可有效预防狂犬病，用于动物多处和严重咬伤的充分浸润，支持稀释做法在实际临床环境中的可行性和安全性。

{"title":"Effectiveness of rabies immunoglobulins and monoclonal antibodies infiltrated into animal bite wounds after dilution: Real-world evidence from an anti-rabies clinic in India","authors":"D.H. Ashwath Narayana , M.K. Poornima , C.M. Chiranthan , H.S. Ravish , Reeta S. Mani , Shrikrishna Isloor , R. Sharada , M.K. Sudarshan","doi":"10.1016/j.vaccine.2026.128233","DOIUrl":"10.1016/j.vaccine.2026.128233","url":null,"abstract":"<div><h3>Background</h3><div>WHO recommends infiltration of category III bite wounds, and category II wounds in immunocompromised individuals, with rabies immunoglobulins (RIG) to neutralize the virus at the site of exposure. Dilution with sterile normal saline is advised to ensure adequate wound infiltration. However, data on the extent of dilution across various RIGs and rabies monoclonal antibodies (RmAbs), and their effectiveness are lacking. This study aimed to generate evidence on dilution practices and outcomes following full-dose infiltration.</div></div><div><h3>Objectives</h3><div>To review the dilution ratios of RIGs and RmAbs used for full-dose wound infiltration in routine practice, and assess the clinical outcomes of the exposed individuals.</div></div><div><h3>Methods</h3><div>A desk review was conducted on 223 animal bite cases managed at an Anti-Rabies Clinic, Bengaluru, India from January 2022 to December 2024. All animal bite victims received full-dose RIG or RmAb, diluted with normal saline as required for complete wound infiltration. Survival status was verified through telephonic follow-up.</div></div><div><h3>Results</h3><div>Of the 223 cases, 133 (60%) were males, 210 (94%) cases had dog bites, 71 (31.8%) had bite from suspect rabid animals.Among 210 cases who had dog bites, 65 (31%) were attributed to suspect rabid dogs. Dilution ratios reached up to 1:1 for HRIG, 1:5.4 for ERIG, 1:20.7 for Rabishield, and 1:8.2 for Twinrab. Special groups included one pregnant woman (Twinrab) and one woman on antiretroviral therapy (Rabishield). Survival was 100%, with no rabies cases observed during 6–42 months of follow-up.</div></div><div><h3>Conclusion</h3><div>Diluted RIGs and RmAbs were found to be effective in preventing rabies when used for adequate infiltration of multiple and severe animal bite wounds, supporting the feasibility and safety of dilution practices in real-world clinical settings.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128233"},"PeriodicalIF":4.5,"publicationDate":"2026-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146038944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-emerging primary trial results from the Bandim health project 班迪姆卫生项目未出现的初步试验结果。

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine

Pub Date : 2026-03-07 Epub Date: 2026-02-04 DOI: 10.1016/j.vaccine.2026.128302

Henrik Støvring , Claus Thorn Ekstrøm , Jesper Wiborg Schneider , Charlotte Strøm

引用次数: 0

Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2–5 years 单价COVID-19 mRNA疫苗接种后美国2-5岁儿童的热性癫痫发作风险

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine

Pub Date : 2026-03-07 Epub Date: 2026-02-04 DOI: 10.1016/j.vaccine.2026.128225

Steven A. Anderson , Elizabeth R. Smith , Zhiruo Wan , Kandace L. Amend , Alex Secora , Djeneba Audrey Djibo , Kamran Kazemi , Jennifer Song , Lauren E. Parlett , John D. Seeger , Nandini Selvam , Cheryl N. McMahill-Walraven , Mao Hu , Yoganand Chillarige , Richard A. Forshee

Objective

To evaluate febrile seizure risk following monovalent COVID-19 mRNA vaccination among children aged 2–5 years.

Methods

The primary analysis evaluated children who had a febrile seizure outcome in the 0–1 days following COVID-19 vaccination. A self-controlled case series analysis was performed in three commercial insurance databases to compare the risk of seizure in the risk interval (0–1 days) to a control interval (8–63 days).

The exposure of interest was receipt of dose 1 and/or dose 2 of monovalent COVID-19 mRNA vaccinations.

The primary outcome was febrile seizure (0–1 day risk interval).

A conditional Poisson regression model was used to compare outcome rates in risk and control intervals and estimate incidence rate ratios (IRR) and 95% confidence intervals (CIs). Meta-analyses were used to pool results across databases.

Results

The primary meta-analysis found a statistically significant increased incidence of febrile seizure, in the 0–1 days following mRNA-1273 vaccination compared to the control interval (IRR: 2.52, 95% CI: 1.35 to 4.69, risk difference (RD)/100,000 doses = 3.22 (95% CI −0.31 to 6.75)). For the BNT162b2 vaccination, the IRR was elevated but not statistically significant (IRR: 1.41, 95% CI: 0.48 to 4.11, RD/100,000 doses = −0.25 (95% CI −2.75 to 2.24).

Conclusions

Among children aged 2–5 years, the analysis showed a small elevated incidence rate ratio of febrile seizures in the 0–1 days following the mRNA-1273 vaccination.

目的：评价2-5岁儿童接种单价COVID-19 mRNA疫苗后的热性惊厥风险。方法：对接种COVID-19疫苗后0 ~ 1天发生发热性惊厥的儿童进行初步分析。在三个商业保险数据库中进行了自我控制的病例系列分析，以比较风险区间（0-1天）和控制区间（8-63天）的癫痫发作风险。感兴趣的暴露是接受单价COVID-19 mRNA疫苗接种剂量1和/或剂量2。主要结局为热性癫痫发作（0-1天风险间隔）。使用条件泊松回归模型比较风险区间和控制区间的转归率，并估计发病率比（IRR）和95%置信区间（ci）。荟萃分析用于跨数据库汇总结果。结果：主要荟萃分析发现，与对照组相比，接种mRNA-1273疫苗后0-1天的发热性惊厥发生率显著增加(IRR: 2.52, 95% CI: 1.35至4.69，风险差异（RD)/100,000剂量= 3.22 (95% CI -0.31至6.75)）。对于BNT162b2疫苗，IRR升高，但没有统计学意义(IRR: 1.41, 95% CI: 0.48至4.11,RD/100,000剂量= -0.25 （95% CI: -2.75至2.24）。结论：在2-5岁儿童中，分析显示接种mRNA-1273疫苗后0-1天的发热性惊厥发生率有小幅升高。

{"title":"Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2–5 years","authors":"Steven A. Anderson , Elizabeth R. Smith , Zhiruo Wan , Kandace L. Amend , Alex Secora , Djeneba Audrey Djibo , Kamran Kazemi , Jennifer Song , Lauren E. Parlett , John D. Seeger , Nandini Selvam , Cheryl N. McMahill-Walraven , Mao Hu , Yoganand Chillarige , Richard A. Forshee","doi":"10.1016/j.vaccine.2026.128225","DOIUrl":"10.1016/j.vaccine.2026.128225","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate febrile seizure risk following monovalent COVID-19 mRNA vaccination among children aged 2–5 years.</div></div><div><h3>Methods</h3><div>The primary analysis evaluated children who had a febrile seizure outcome in the 0–1 days following COVID-19 vaccination. A self-controlled case series analysis was performed in three commercial insurance databases to compare the risk of seizure in the risk interval (0–1 days) to a control interval (8–63 days).</div><div>The exposure of interest was receipt of dose 1 and/or dose 2 of monovalent COVID-19 mRNA vaccinations.</div><div>The primary outcome was febrile seizure (0–1 day risk interval).</div><div>A conditional Poisson regression model was used to compare outcome rates in risk and control intervals and estimate incidence rate ratios (IRR) and 95% confidence intervals (CIs). Meta-analyses were used to pool results across databases.</div></div><div><h3>Results</h3><div>The primary meta-analysis found a statistically significant increased incidence of febrile seizure, in the 0–1 days following mRNA-1273 vaccination compared to the control interval (IRR: 2.52, 95% CI: 1.35 to 4.69, risk difference (RD)/100,000 doses = 3.22 (95% CI −0.31 to 6.75)). For the BNT162b2 vaccination, the IRR was elevated but not statistically significant (IRR: 1.41, 95% CI: 0.48 to 4.11, RD/100,000 doses = −0.25 (95% CI −2.75 to 2.24).</div></div><div><h3>Conclusions</h3><div>Among children aged 2–5 years, the analysis showed a small elevated incidence rate ratio of febrile seizures in the 0–1 days following the mRNA-1273 vaccination.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128225"},"PeriodicalIF":4.5,"publicationDate":"2026-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146128126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0